Successful Treatment of Somnambulism With OROS-Methylphenidate
Somnambulism is a non-rapid eye movement sleep parasomnia with potential for significant injury as well as functional nighttime and daytime impairment. Clonazepam is frequently used as first line pharmacotherapy. However, the optimal treatment of somnambulism has not been established. In this article, we present the cases of two patients with severe somnambulism who showed a significant therapeutic response to osmotic release oral system methylphenidate (OROS-MPH). In addition to its practical therapeutic implications, this first report of the successful treatment of somnambulism with OROS-MPH may provide additional insight into the neurobiological underpinnings of this medical condition.
Nigam M, Zadra A, Boucetta S, Gibbs SA, Montplaisir J, Desautels A. Successful treatment of somnambulism with OROS-methylphenidate. J Clin Sleep Med. 2019;15(11):1683–1685.
Please login to continue reading the full article
Subscribers to JCSM get full access to current and past issues of the JCSM.
Login to JCSM
Not a subscriber?
Join the American Academy of Sleep Medicine and receive a subscription to JCSM with your membership
Subscribe to JCSM:
$125/volume year for individuals or $225/volume year for institutions to access all current articles and archives published in JCSM.
Download this article*:
$20 to access a PDF version of a specific article from the current issue of JCSM.
*Purchase of an article provides permission to access and print the article for personal scholarly, research and educational use. Please note: access to the article is from the computer on which the article is purchased ONLY. Purchase of the article does not permit distribution, electronic or otherwise, of the article without the written permission of the AASM. Further, purchase does not permit the posting of article text on an online forum or website.